Journal Mobile Options
Table of Contents
Vol. 81, No. 2, 2011
Issue release date: October 2011
Oncology 2011;81:79–83

Acute and Delayed Complications from Surgery and Adjuvant Radiotherapy in the Treatment of High-Risk Endometrial Cancer

Mendivil A.A. · Rettenmaier M.A. · Cox C. · Abaid L.N. · Brown III J.V. · Micha J.P. · Lopez K.L. · Goldstein B.H.
aGynecologic Oncology Associates, bDepartment of Radiation Oncology, Hoag Hospital, and cWomen’s Cancer Research Foundation, Newport Beach, Calif., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objectives: This retrospective study assessed the number and type of complications following surgery and adjuvant radiotherapy in the treatment of high-risk endometrial cancer. Methods: Endometrial cancer patients who received surgery and postoperative radiotherapy (pelvic radiotherapy and/or vaginal brachytherapy) from April 1997 until October 2010 were evaluated. Short-term (≤6 months) and long-term (>6 months) complications (e.g., genitourinary/gastrointestinal complications) were comprehensively reviewed. Results: We identified 109 high-risk endometrial cancer patients who completed adjuvant radiotherapy following either a total abdominal hysterectomy (TAH; n = 53) or minimally invasive hysterectomy (MIS; n = 56). The combined impact of surgery and radiotherapy on complication type did not reach statistical significance (p > 0.05). However, surgery type and the development of a complication were significantly related (p < 0.001). The MIS patients developed complications at a more accelerated rate compared to the TAH patients (21 vs. 45 months), although the incidence of toxicity of grade 3 or 4 was much higher in the TAH group. Conclusions: The impact of MIS and adjuvant radiotherapy may have adversely affected the development of complications compared to TAH patients who received adjuvant radiotherapy, although higher-grade patient toxicity was more prevalent in the TAH group.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
  2. Eiriksson L, Cuartero J, Steed H, Pearcey R, Capstick V, Schepansky A, et al: Assessment of outcomes in surgically staged I/II endometrial adenocarcinoma patients treated with postoperative vaginal vault radiotherapy only. Int J Gynecol Cancer2010;20:1356–1362.

    External Resources

  3. Gaia G, Holloway RW, Santoro L, Ahmad S, Di Silverio E, Spinillo A: Robotic-assisted hysterectomy for endometrial cancer compared with traditional laparoscopic and laparotomy approaches: a systematic review. Obstet Gynecol 2010;116:1422–1431.
  4. ASTEC/EN.5 Study Group, Blake P, Swart AM, Orton J, Kitchener H, Whelan T, et al: Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009;373:137–146.
  5. Scotti V, Borghesi S, Meattini I, Saieva C, Rossi F, Petrucci A, et al: Postoperative radiotherapy in stage I/II endometrial cancer: retrospective analysis of 883 patients treated at the University of Florence. Int J Gynecol Cancer2010;20:1540–1548.

    External Resources

  6. Hsu WC, Chung NN, Chen YC, Ting LL, Wang PM, Hsieh PC, et al: Comparison of surgery or radiotherapy on complications and quality of life in patients with the stage IB and IIA uterine cervical cancer. Gynecol Oncol 2009;115:41–45.
  7. Chen MC, Chiang FF, Hsu TW, Chen JB, Chao TH, Ma HF, et al: Clinical experience in 89 consecutive cases of chronic radiation enterocolitis. J Chin Med Assoc 2011;74:69–74.
  8. NIH Common Terminology Criteria for Adverse Events (CTCAE v4.0). Washington, National Institutes of Health, 2009.
  9. Barillot I, Maingon P: Endometrial carcinoma: which radiotherapy for which patient (in French). Cancer Radiother 2003;7(suppl 1): 1–7.
  10. Holland C: Unresolved issues in the management of endometrial cancer. Expert Rev Anticancer Ther 2011;11:57–69.
  11. Kong A, Powell M, Blake P: The role of postoperative radiotherapy in carcinoma of the endometrium. Clin Oncol (R Coll Radiol) 2008;20:457–462.
  12. Macchia G, Ferrandina G, Deodato F, Bibbò R, Massaccesi M, Ippolito E, et al: 3D conformal postoperative radiotherapy with concomitant boost in uterine cancer: results of a phase I-II study (ADA-RT-1). Gynecol Oncol 2011;120:485–488.
  13. Bell MC, Torgerson J, Seshadri-Kreaden U, Suttle AW, Hunt S: Comparison of outcomes and cost for endometrial cancer staging via traditional laparotomy, standard laparoscopy and robotic techniques. Gynecol Oncol 2008;111:407–411.
  14. Abdelmonem A, Wilson H, Pasic R: Observational comparison of abdominal, vaginal and laparoscopic hysterectomy as performed at a university teaching hospital. J Reprod Med 2006;51:945–954.
  15. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al: A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:744–751.
  16. Nick AM, Lange J, Frumovitz M, Soliman PT, Schmeler KM, Schlumbrecht MP, et al: Rate of vaginal cuff separation following laparoscopic or robotic hysterectomy. Gynecol Oncol 2011;120:47–51.
  17. Magrina JF, Kho RM, Weaver AL, Montero RP, Magtibay PM: Robotic radical hysterectomy: comparison with laparoscopy and laparotomy. Gynecol Oncol 2008;109:86–91.
  18. Chung YL, Jian JJ, Cheng SH, Hsieh CI, Tan TD, Chang HJ, et al: Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study. Gynecol Oncol 2005;97:126–135.
  19. Matsushita K, Ochiai T, Shimada H, Kato S, Ohno T, Nikaido T, et al: The effects of carbon ion irradiation revealed by excised perforated intestines as a late morbidity for uterine cancer treatment. Surg Today 2006;36:692–700.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50